Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded at Barclays

Barclays upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) to a strong-buy rating in a research report report published on Monday,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. The Goldman Sachs Group upped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday. UBS Group upped their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Finally, JPMorgan Chase & Co. increased their price objective on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $30.25.

Teva Pharmaceutical Industries Stock Up 4.1%

TEVA stock opened at $29.74 on Monday. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31. Teva Pharmaceutical Industries has a twelve month low of $12.47 and a twelve month high of $29.80. The company’s 50 day moving average is $23.03 and its two-hundred day moving average is $19.44. The stock has a market cap of $34.10 billion, a P/E ratio of 49.56, a PEG ratio of 1.53 and a beta of 0.67.

Insider Activity

In other news, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the completion of the sale, the director owned 495,000 shares in the company, valued at $11,934,450. This represents a 28.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.49% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently bought and sold shares of the company. Bourgeon Capital Management LLC boosted its holdings in Teva Pharmaceutical Industries by 100.7% in the 2nd quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company’s stock valued at $12,134,000 after purchasing an additional 363,252 shares in the last quarter. Amundi raised its stake in shares of Teva Pharmaceutical Industries by 18.5% during the 1st quarter. Amundi now owns 678,758 shares of the company’s stock worth $10,080,000 after buying an additional 105,846 shares in the last quarter. IFM Investors Pty Ltd lifted its holdings in shares of Teva Pharmaceutical Industries by 9.4% in the 2nd quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company’s stock valued at $3,797,000 after buying an additional 19,447 shares during the period. Vontobel Holding Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 5.5% in the 2nd quarter. Vontobel Holding Ltd. now owns 719,676 shares of the company’s stock valued at $12,062,000 after buying an additional 37,455 shares during the period. Finally, Jump Financial LLC boosted its stake in shares of Teva Pharmaceutical Industries by 172.1% in the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company’s stock valued at $20,373,000 after buying an additional 838,423 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.